"I have worked at Genentech for close to 29 years, when people ask me why I stay my answer is straightforward: The commitment to patients, the myriad of learning opportunities, and the endless possibilities to contribute to advance science. I have enjoyed the evolution of Genentech and the drive of the people I am surrounded by – all with a common purpose. When I was at the bench years ago, testing samples from clinical study subjects, and later being told by a friend of the family of their participation on one of those clinical studies it made it “REAL” for me. We are here to help patients who are people just like each of us – that inspires me."
I joined Genentech in the late 1980’s, and am proud of having started “at the bench” initially working with Process Development and later transitioning to non-clinical and clinical Product Development. I have a successful track record with bio-therapeutic development, bioanalysis, compliance, IT and automation, having made significant contributions to some of Genentech’s product approvals, and to a large number of molecules in world-wide development in the areas of oncology, autoimmunity, asthma, and pain.
Today, I am the Senior Director of BioAnalytical Sciences; a top-notch department dedicated to enable drug development by providing key data for non-clinical and clinical studies for all Genentech molecules from late stage research through post marketing.
One of my key deliverable is set the strategic direction of the organization to meet the ever-changing business needs, while continue to provide high quality data using proven, as well as, state of the art technologies.
Bioanalysis. 2013 May;5(9):997-1006.
As the leader of the BioAnalytical Sciences Department at Genentech one of my key deliverable is to set the strategic direction of the organization to meet the ever-changing business needs, while continue to provide high quality data using proven, as well as, state of the art technologies.
My team members set strategies for the development and implementation of bioanalytical assays including for pharmacokinetic determinations, and in-vitro characterization of Genentech molecules. They also set immunogenicity strategies for all our biotherapeutics, develop methods, generate and interpret immunogenicity data, partnering with others within Genentech. The department’s scope includes development and implementation of pharmacodynamics biomarker assays specifically using Immunoassay technologies.
As part of my focus I have developed an outsourcing strategy to ensure the pipeline portfolio needs are met, while ensuring internal talent is focused on advancement of technologies, project facing needs to continue enabling getting medicines to patients.